Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why
Exelixis (EXEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
EXEL or ARGX: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
3 Stocks With Upgraded Broker Ratings to Consider for Solid Returns
EXEL, LYFT and KGC have all seen notable broker upgrades recently. Here???s why they may offer solid returns ahead.
3 Reasons Growth Investors Will Love Exelixis (EXEL)
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment
Exelixis is a strong buy due to robust CABOMETYX sales growth, with Q1 2025 revenues up 36% year-over-year and raised full-year 2025 guidance. Positive phase 3 STELLAR-303 results for zanzalintinib plus TECENTRIQ in non-MSI-high metastatic colorectal cancer opens significant new market opportunities. Expansion of the zanzalintinib pipeline into additional indications (nccRCC, HNSCC) and ongoing regulatory milestones could further drive shareholder value.
Here's Why Exelixis (EXEL) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL or ARGX: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)
Exelixis (EXEL) possesses solid growth attributes, which could help it handily outperform the market.
Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great Choice
Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
